1
|
Carpi S, Polini B, Fogli S, Podestà A, Ylösmäki E, Cerullo V, Romanini A, Nieri P. Circulating microRNAs as biomarkers for early diagnosis of cutaneous melanoma. Expert Rev Mol Diagn 2019; 20:19-30. [PMID: 31747311 DOI: 10.1080/14737159.2020.1696194] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Introduction: Cutaneous melanoma is the deadliest form of skin cancer, with a dramatic increase in the incidence rate worldwide over the past decade. Early detection has been shown to improve the outcome of melanoma patients. The identification of noninvasive biomarkers able to identify melanoma at an early stage remains an unmet clinical need. Circulating miRNAs (c-miRNAs), small non-coding RNAs, appear as potential ideal candidate biomarkers due to their stability in biological fluids and easy detectability. Moreover, c-miRNAs are reported to be heavily deregulated in cancer patients.Areas covered: This review examines evidence of the specific c-miRNAs or panels of c-miRNAs reported to be useful in discriminating melanoma from benign cutaneous lesions.Expert opinion: Although the interesting reported by published studies, the non-homogeneity of detection and normalization methods prevents the individuation of single c-miRNA or panel of c-miRNAs that are specific for early detection of cutaneous melanoma. In the future, prospective wide and well-designed clinical trials will be needed to validate the diagnostic potential of some of the c-miRNA candidates in clinical practice.
Collapse
Affiliation(s)
- Sara Carpi
- Department of Pharmacy, University of Pisa, Pisa, Italy
| | | | - Stefano Fogli
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Adriano Podestà
- Department of Veterinary Science, University of Pisa, Pisa, Italy
| | - Erkko Ylösmäki
- Drug Research program and IVTLab, University of Helsinki, Helsinki, Finland
| | - Vincenzo Cerullo
- Drug Research program and IVTLab, University of Helsinki, Helsinki, Finland
| | | | - Paola Nieri
- Department of Pharmacy, University of Pisa, Pisa, Italy
| |
Collapse
|
2
|
Hao H, Liu L, Zhang D, Wang C, Xia G, Zhong F, Hu X. Diagnostic and prognostic value of miR-106a in colorectal cancer. Oncotarget 2018; 8:5038-5047. [PMID: 27926519 PMCID: PMC5354890 DOI: 10.18632/oncotarget.13766] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2016] [Accepted: 11/22/2016] [Indexed: 01/11/2023] Open
Abstract
We sought to systematically evaluate the diagnostic and prognostic value miR106a in patients with colorectal cancer (CRC). An original study was conducted to explore correlations between tissue miR106a levels and outcomes for 138 patients diagnosed with CRC. To explore the diagnostic performance of miR106a, eligible studies were identified from medical databases from China and abroad. Based on these results, 15 studies (including our original study) were pooled and included in a meta-analyses. The pooled sensitivity, specificity, and diagnostic odds ratios of miR106a were 0.53 (95% confidence interval (CI): 0.49–0.57), 0.85 (95% CI: 0.82–0.88), and 7.22 (95% CI: 3.17–16.44) for diagnosis of CRC, and the area under the curve (AUC) for miR106a when diagnosing CRC was 0.72. Patients with higher expression of tissue miR106a had poor overall survival (pooled hazard ratio (HR): 1.50; 95% CI: 1.02–2.20), but not disease-free survival (pooled HR: 1.03; 95% CI: 0.40–2.65). Overexpression of miR106a may predict superior metastasis-free survival (pooled HR: 0.65; 95% CI: 0.33–1.27), but the effect was not significant in this study (p = 0.21).
Collapse
Affiliation(s)
- Haibin Hao
- Department of General Surgery, Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Laipeng Liu
- Department of General Surgery, Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Dong Zhang
- Department of General Surgery, Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Chao Wang
- Department of General Surgery, Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Guangfeng Xia
- Department of General Surgery, Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Fuping Zhong
- Department of General Surgery, Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Xiaoyun Hu
- Department of General Surgery, Second Affiliated Hospital of Nanchang University, Nanchang, China
| |
Collapse
|
3
|
Zhou P, Tu L, Lin X, Hao X, Zheng Q, Zeng W, Zhang X, Zheng Y, Wang L, Li S. cfa-miR-143 Promotes Apoptosis via the p53 Pathway in Canine Influenza Virus H3N2-Infected Cells. Viruses 2017; 9:v9120360. [PMID: 29186842 PMCID: PMC5744135 DOI: 10.3390/v9120360] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Revised: 11/16/2017] [Accepted: 11/21/2017] [Indexed: 12/25/2022] Open
Abstract
MicroRNAs regulate multiple aspects of the host response to viral infection. This study verified that the expression of cfa-miR-143 was upregulated in vivo and in vitro by canine influenza virus (CIV) H3N2 infection. To understand the role of cfa-miR-143 in CIV-infected cells, the target gene of cfa-miR-143 was identified and assessed for correlations with proteins involved in the apoptosis pathway. A dual luciferase reporter assay showed that cfa-miR-143 targets insulin-like growth factor binding protein 5 (Igfbp5). Furthermore, a miRNA agomir and antagomir of cfa-miR-143 caused the downregulation and upregulation of Igfbp5, respectively, in CIV-infected madin-darby canine kidney (MDCK) cells. This study demonstrated that cfa-miR-143 stimulated p53 and caspase3 activation and induced apoptosis via the p53 pathway in CIV H3N2-infected cells. In conclusion, CIV H3N2 induced the upregulation of cfa-miR-143, which contributes to apoptosis via indirectly activating the p53-caspase3 pathway.
Collapse
Affiliation(s)
- Pei Zhou
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China.
- Guangdong Provincial Key Laboratory of Prevention and Control for Severe Clinical Animal Diseases, Guangzhou 510642, China.
- Guangdong Provincial Pet Engineering Technology Research Center, Guangzhou 510642, China.
| | - Liqing Tu
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China.
- Guangdong Provincial Key Laboratory of Prevention and Control for Severe Clinical Animal Diseases, Guangzhou 510642, China.
- Guangdong Provincial Pet Engineering Technology Research Center, Guangzhou 510642, China.
| | - Xi Lin
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China.
- Guangdong Provincial Key Laboratory of Prevention and Control for Severe Clinical Animal Diseases, Guangzhou 510642, China.
- Guangdong Provincial Pet Engineering Technology Research Center, Guangzhou 510642, China.
| | - Xiangqi Hao
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China.
- Guangdong Provincial Key Laboratory of Prevention and Control for Severe Clinical Animal Diseases, Guangzhou 510642, China.
- Guangdong Provincial Pet Engineering Technology Research Center, Guangzhou 510642, China.
| | - Qingxu Zheng
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China.
- Guangdong Provincial Key Laboratory of Prevention and Control for Severe Clinical Animal Diseases, Guangzhou 510642, China.
- Guangdong Provincial Pet Engineering Technology Research Center, Guangzhou 510642, China.
| | - Weijie Zeng
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China.
- Guangdong Provincial Key Laboratory of Prevention and Control for Severe Clinical Animal Diseases, Guangzhou 510642, China.
- Guangdong Provincial Pet Engineering Technology Research Center, Guangzhou 510642, China.
| | - Xin Zhang
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China.
- Guangdong Provincial Key Laboratory of Prevention and Control for Severe Clinical Animal Diseases, Guangzhou 510642, China.
- Guangdong Provincial Pet Engineering Technology Research Center, Guangzhou 510642, China.
| | - Yun Zheng
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China.
- Guangdong Provincial Key Laboratory of Prevention and Control for Severe Clinical Animal Diseases, Guangzhou 510642, China.
- Guangdong Provincial Pet Engineering Technology Research Center, Guangzhou 510642, China.
| | - Lifang Wang
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China.
- Guangdong Provincial Key Laboratory of Prevention and Control for Severe Clinical Animal Diseases, Guangzhou 510642, China.
- Guangdong Provincial Pet Engineering Technology Research Center, Guangzhou 510642, China.
| | - Shoujun Li
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China.
- Guangdong Provincial Key Laboratory of Prevention and Control for Severe Clinical Animal Diseases, Guangzhou 510642, China.
- Guangdong Provincial Pet Engineering Technology Research Center, Guangzhou 510642, China.
| |
Collapse
|
4
|
Evaluation of miRNA-196a2 and apoptosis-related target genes: ANXA1, DFFA and PDCD4 expression in gastrointestinal cancer patients: A pilot study. PLoS One 2017; 12:e0187310. [PMID: 29091952 PMCID: PMC5665540 DOI: 10.1371/journal.pone.0187310] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2017] [Accepted: 10/17/2017] [Indexed: 12/26/2022] Open
Abstract
Previous reports have suggested the significant association of miRNAs aberrant expression with tumor initiation, progression and metastasis in cancer, including gastrointestinal (GI) cancers. The current preliminary study aimed to evaluate the relative expression levels of miR-196a2 and three of its selected apoptosis-related targets; ANXA1, DFFA and PDCD4 in a sample of GI cancer patients. Quantitative real-time PCR for miR-196a2 and its selected mRNA targets, as well as immunohistochemical assay for annexin A1 protein expression were detected in 58 tissues with different GI cancer samples. In addition, correlation with the clinicopathological features and in silico network analysis of the selected molecular markers were analyzed. Stratified analyses by cancer site revealed elevated levels of miR-196a2 and low expression of the selected target genes. Annexin protein expression was positively correlated with its gene expression profile. In colorectal cancer, miR-196a over-expression was negatively correlated with annexin A1 protein expression (r = -0.738, p < 0.001), and both were indicators of unfavorable prognosis in terms of poor differentiation, larger tumor size, and advanced clinical stage. Taken together, aberrant expression of miR-196a2 and the selected apoptosis-related biomarkers might be involved in GI cancer development and progression and could have potential diagnostic and prognostic roles in these types of cancer; particularly colorectal cancer, provided the results experimentally validated and confirmed in larger multi-center studies.
Collapse
|
5
|
Ye H, Hao H, Wang J, Chen R, Huang Z. miR-203 as a novel biomarker for the diagnosis and prognosis of colorectal cancer: a systematic review and meta-analysis. Onco Targets Ther 2017; 10:3685-3696. [PMID: 28769572 PMCID: PMC5533489 DOI: 10.2147/ott.s134252] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
We sought to systematically evaluate the diagnostic and prognostic value of miR-203 in patients with colorectal cancer. To explore the diagnostic performance of miR-203, eligible studies were identified from biomedical databases. Based on these results, 11 studies were pooled and included in this meta-analysis. The pooled sensitivity, specificity, and diagnostic odds ratios of miR-203 were 0.83 (95% confidence interval, CI: 0.78–0.86), 0.80 (95% CI: 0.77–0.83), and 19.27 (95% CI: 7.23–51.36) for the diagnosis of colorectal cancer. The area under the curve for miR-203 for diagnosing colorectal cancer was 0.89. Patients with higher expression of tissue miR-203 had poor overall survival (pooled hazard ratio: 1.63; 95% CI: 1.03–2.57, P=0.04), but serum miR-203 was not predictive (pooled hazard ratio: 1.59; 95% CI: 0.31–8.12, P=0.58). The miR-203 values of tissue and serum merged together may perhaps predict superior overall survival (pooled hazard ratio: 1.62; 95% CI: 0.93–2.82), but the effect was not significant (P=0.09).
Collapse
Affiliation(s)
- Huajun Ye
- Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang
| | - Haibin Hao
- Department of General Surgery, Medical College of Nanchang University, Nanchang
| | - Jincheng Wang
- Department of Medical Imaging, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, People's Republic of China
| | - Renpin Chen
- Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang
| | - Zhiming Huang
- Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang
| |
Collapse
|
6
|
Armand-Labit V, Pradines A. Circulating cell-free microRNAs as clinical cancer biomarkers. Biomol Concepts 2017; 8:61-81. [DOI: 10.1515/bmc-2017-0002] [Citation(s) in RCA: 113] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2017] [Accepted: 03/21/2017] [Indexed: 12/23/2022] Open
Abstract
AbstractMicroRNAs (miRNAs) are non-coding small RNAs that are master regulators of genic expression and consequently of many cellular processes. But their expression is often deregulated in human tumors leading to cancer development. Recently miRNAs were discovered in body fluids (serum, plasma and others) and their levels have often been reported to be altered in patients. Circulating miRNAs became one of the most promising biomarkers in oncology for early diagnosis, prognosis and therapeutic response prediction. Here we describe the origins and roles of miRNAs, and summarize the most recent studies focusing on their usefulness as cancer biomarkers in lung, breast, colon, prostate, ovary cancers and melanoma. Lastly, we describe the main methodologies related to miRNA detection, which should be standardized for their use in clinical practice.
Collapse
Affiliation(s)
- Virginie Armand-Labit
- Inserm, Centre de Recherche en Cancérologie de Toulouse, CRCT UMR-1037, Toulouse, France
- Institut Claudius Regaud, IUCT-Oncopole, Laboratoire de Biologie Médicale Oncologique, Toulouse, France
| | - Anne Pradines
- Inserm, Centre de Recherche en Cancérologie de Toulouse, CRCT UMR-1037, Toulouse, France
- Institut Claudius Regaud, IUCT-Oncopole, Laboratoire de Biologie Médicale Oncologique, Toulouse, France
| |
Collapse
|
7
|
Köberle V, Kakoschky B, Ibrahim AA, Schmithals C, Peveling-Oberhag J, Zeuzem S, Kronenberger B, Waidmann O, Pleli T, Piiper A. Vesicle-associated microRNAs are released from blood cells on incubation of blood samples. Transl Res 2016; 169:40-6. [PMID: 26608461 DOI: 10.1016/j.trsl.2015.10.010] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/22/2015] [Revised: 10/26/2015] [Accepted: 10/29/2015] [Indexed: 01/09/2023]
Abstract
MicroRNAs (miRNAs) circulating extracellularly in the blood are currently intensively studied as novel disease markers. However, the preanalytical factors influencing the levels of the extracellular miRNAs are still incompletely explored. In particular, it is unknown, whether the incubation of blood samples as occurring in clinical routine can lead to a release of miRNAs from blood cells and thus alter the extracellular miRNA levels before the preparation of serum or plasma from the blood cells. Using a set of marker miRNAs and quantitative RT-PCR, we found that the levels of extracellular miRNA-1, miRNA-16, and miRNA-21 were increased in EDTA and serum collection tubes incubated for 1-3 hours at room temperature and declined thereafter; the levels of the liver-specific miRNA-122 declined monophasically. These events occurred in the absence of significant hemolysis. When the blood was supplemented with Ribonuclease A inhibitor, the levels of miRNA-1, miRNA-16, and miRNA-21 increased substantially during the initial 3 hours of incubation and those of miRNA-122 remained unchanged, indicating that the release of blood cell-derived miRNAs occurred during the initial 3 hours of incubation of the blood tubes, but not at later time points. Separation of 5-hour preincubated blood into vesicle and nonvesicle fractions revealed a selective increase in the portion of vesicle-associated miRNAs. Together, these data indicate that the release of vesicle-associated miRNAs from blood cells can occur in blood samples within the time elapsing in normal clinical practice until their processing without significant hemolysis. This becomes particularly visible on the inhibition of miRNA degradation by Ribonuclease A inhibitor.
Collapse
Affiliation(s)
- Verena Köberle
- Department of Medicine I, University Hospital Frankfurt, Frankfurt, Germany
| | - Bianca Kakoschky
- Department of Medicine I, University Hospital Frankfurt, Frankfurt, Germany
| | - Ahmed Atef Ibrahim
- Department of Medicine I, University Hospital Frankfurt, Frankfurt, Germany
| | | | | | - Stefan Zeuzem
- Department of Medicine I, University Hospital Frankfurt, Frankfurt, Germany
| | - Bernd Kronenberger
- Department of Medicine I, University Hospital Frankfurt, Frankfurt, Germany
| | - Oliver Waidmann
- Department of Medicine I, University Hospital Frankfurt, Frankfurt, Germany
| | - Thomas Pleli
- Department of Medicine I, University Hospital Frankfurt, Frankfurt, Germany
| | - Albrecht Piiper
- Department of Medicine I, University Hospital Frankfurt, Frankfurt, Germany.
| |
Collapse
|